|
業務類別
|
Biotechnology |
|
業務概覽
|
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older. |
| 公司地址
| 55 Cambridge Parkway, Suite 901 East, Cambridge, MA, USA, 02142 |
| 電話號碼
| +1 857 999-0075 |
| 傳真號碼
| +1 866 553-3269 |
| 公司網頁
| https://www.kalvista.com |
| 員工數量
| 270 |
| Mr. Benjamin L. Palleiko |
Chief Executive Officer and Director |
美元 688.27K |
25/03/2026 |
| Mr. Bilal Arif |
Chief Operating Officer |
-- |
06/10/2025 |
| Dr. Paul K. Audhya, M.B.A.,M.D. |
Chief Medical Officer |
美元 523.02K |
21/08/2025 |
| Mr. Christopher M. Yea, PhD |
Chief Development Officer |
-- |
21/08/2025 |
| Mr. Brian Piekos |
Chief Financial Officer and Principal Accounting Officer |
美元 296.35K |
25/03/2026 |
| Ms. Nicole Sweeny |
Chief Commercial Officer |
-- |
21/08/2025 |
|
|
| Mr. Benjamin L. Palleiko |
Chief Executive Officer and Director |
25/03/2026 |
| Dr. Brian J.G. Pereira,M.D. |
Chairman of the Board |
25/03/2026 |
| Mr. William Carl Fairey, Jr |
Independent Director |
25/03/2026 |
| Mr. Edward W. Unkart |
Independent Director |
25/03/2026 |
| Ms. Nancy Stuart |
Independent Director |
25/03/2026 |
| Mr. Patrick Treanor, M.B.A. |
Independent Director |
25/03/2026 |
| Dr. Laurence E. Reid, PhD |
Independent Director |
25/03/2026 |
| Ms. Bethany L. Sensenig |
Independent Director |
02/10/2025 |
|
|
|
|
